Patient characteristics for anti-CTLA4 and anti-PD1 cohorts
| Anti-PD1 | Anti-CTLA4 | |
|---|---|---|
| Patient characteristics | N (%) | N (%) |
| Age, years | ||
| <40 | 2 (5.3) | 3 (7.1) |
| 40–55 | 11 (28.9) | 14 (33.3) |
| 56–70 | 14 (36.8) | 18 (42.9) |
| >70 | 11 (28.9) | 7 (16.7) |
| Gender | ||
| Male | 27 (71.1) | 23 (54.8) |
| Female | 11 (28.9) | 19 (45.2) |
| PFS | ||
| <3 months | 9 (23.7) | 13 (59.1) |
| 3–9 months | 11 (28.9) | 6 (27.3) |
| >9 months | 18 (47.4) | 3 (13.6) |
| RECIST1.1 at ∼12 weeks | ||
| CR | 1 (2.6) | 2 (4.8) |
| PR | 11 (28.9) | 10 (23.8) |
| SD | 12 (31.6) | 3 (7.1) |
| PD | 14 (36.8) | 27 (64.3) |
| BRAF mutation status | ||
| Wild-type | 27 (73.0) | |
| Mutated | 10 (27.0) | |
| NRAS mutation status | ||
| Wild-type | 21 (60.0) | |
| Mutated | 14 (40.0) | |
| Previous treatments | ||
| Chemotherapy | 3 (7.9) | |
| Targeted therapy | 2 (5.3) | |
| Immunotherapy (ipilimumab) | 28 (73.7) | |
| Radiotherapy | 4 (10.5) | |
| Interferon | 1 (2.6) | |
| Lactate dehydrogenase (LDH/ULN) | ||
| <1 | 20 (54.1) | 27 (67.5) |
| ≥1 | 17 (45.9) | 13 (32.5) |
| S100 | ||
| <0.2 μg/L | 10 (27.8) | |
| ≥0.2 μg/L | 26 (72.2) | |
| ANC | ||
| <8 g/L | 35 (92.1) | 40 (95.2) |
| ≥8 g/L | 3 (7.9) | 2 (4.8) |
| ALC | ||
| <1.5 g/L | 25 (65.8) | 28 (66.7) |
| ≥1.5 g/L | 13 (34.2) | 14 (33.3) |
| Leukocytes | ||
| <9.6 g/L | 34 (89.5) | |
| ≥9.6 g/L | 4 (10.5) | |
| Basophils | ||
| <0.15 g/L | 20 (52.6) | |
| ≥0.15 g/L | 18 (47.4) | |
| Eosinophils | ||
| <0.7 g/L | 36 (94.7) | |
| ≥0.7 g/L | 2 (5.3) | |
NOTE: N, number of patients in each category. %, representation in percent for each category.